The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

[1]  Robert J Anderson,et al.  Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. , 2004, Journal of the American College of Cardiology.

[2]  P. Widimsky,et al.  One-Year Coronary Bypass Graft Patency: A Randomized Comparison Between Off-Pump and On-Pump Surgery Angiographic Results of the PRAGUE-4 Trial , 2004, Circulation.

[3]  C David Naylor,et al.  A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. , 2004, The New England journal of medicine.

[4]  J. Bett,et al.  Five-Year Angiographic Patency of Radial Artery Bypass Grafts , 2004, Circulation.

[5]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[6]  R. M. Satava,et al.  Disruptive visions: Biosurgery , 2003, Surgical Endoscopy And Other Interventional Techniques.

[7]  M. Mann,et al.  Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. , 2001, The Journal of thoracic and cardiovascular surgery.

[8]  M. Mann,et al.  Therapeutic applications of transcription factor decoy oligonucleotides. , 2000, The Journal of clinical investigation.

[9]  M. Mann,et al.  Gene therapy for vein grafts , 2000, Current cardiology reports.

[10]  J. Polak,et al.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial , 1999, The Lancet.

[11]  J. Alpert,et al.  ACC/AHA guidelines for coronary artery bypass graft surgery , 1999 .

[12]  H. Hutchinson,et al.  Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Le May,et al.  Predictors of long-term outcome after stent implantation in a saphenous vein graft. , 1999, The American journal of cardiology.

[14]  N. Tomita,et al.  An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. , 1998, American journal of physiology. Renal physiology.

[15]  M. Mann,et al.  Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.

[16]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[17]  M. Leon,et al.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. , 1997, The New England journal of medicine.

[18]  L. Conklin,et al.  Coronary artery bypass conduits: review of current status. , 1997, The Journal of cardiovascular surgery.

[19]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[20]  P. Stein,et al.  Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. , 1995, Chest.

[21]  R. Califf,et al.  Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. , 1995, Circulation.

[22]  J. Nevins,et al.  Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes , 1995, Molecular and cellular biology.

[23]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Tsao,et al.  Genetic engineering of vein grafts resistant to atherosclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[26]  J. Wilson,et al.  Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. , 1994, Circulation.

[27]  E. Jones,et al.  Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts. , 1994, The American journal of cardiology.

[28]  M. Pfisterer,et al.  Prevention of one-year vein-graft occlusion after aortocoronary- bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants , 1993, The Lancet.

[29]  L. Campeau,et al.  Long-term angiographic follow-up after angioplasty of venous coronary bypass grafts. , 1991, American Heart Journal.

[30]  A. Gotlieb,et al.  Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. , 1991, Progress in cardiovascular diseases.

[31]  F. Loop,et al.  Reoperation for Coronary Atherosclerosis: Changing Practice in 2509 Consecutive Patients , 1990, Annals of surgery.

[32]  J. Copeland,et al.  Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. , 1989, Circulation.

[33]  L. Campeau,et al.  Coronary artery bypass grafting with saphenous vein. , 1989, Circulation.

[34]  G. E. Green,et al.  Reoperation for coronary artery disease. 10 years of clinical follow-up. , 1988, Circulation.

[35]  Thomas E. Moritz,et al.  Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. , 1988, Circulation.

[36]  M. Adams,et al.  Kinetics of vein graft hyperplasia: association with tangential stress. , 1987, Journal of vascular surgery.

[37]  W. Keon,et al.  Coronary bypass graft fate. Angiographic study of 1,179 vein grafts early, one year, and five years after operation. , 1986, The Journal of thoracic and cardiovascular surgery.

[38]  S. Wacholder,et al.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. , 1984, The New England journal of medicine.

[39]  M. Bourassa,et al.  Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation. , 1984, Circulation.